Contact us 24/7


Benlysta Linked to Increased Risk of Suicide and Death

Benlysta (belimumab) is a drug marketed by Human Genome Sciences as an adjunct treatment to be taken in addition to standard systemic lupus erythematosus treatment. However, clinical data suggests that treatment with Benlysta may be ineffective and may result in an increased risk of suicide and death.

According to documents released by the U.S. Food and Drug Administration (FDA), a total of 26 deaths were recorded among patients taking Benlysta during clinical trials. By comparison, only four deaths were recorded among placebo groups. The same documents showed that three of the 26 Benlysta patient deaths were suicides, while no suicides were recorded in the placebo groups.

Additionally, analysts noted that patients taking Benlysta were more likely to experience psychiatric events – there has been no explanation of the increased rate of neuropsychiatric events.


Among the side effects experienced by patients taking Benlysta are:

  • Nausea
  • Headache
  • Fatigue
  • Chest pain
  • Edema
  • Depression
  • Hypersensitivity
  • Loss of consciousness
  • Bone pain
  • Panic attack
  • Convulsion
  • Suicide
  • Death


If you’ve been injured, we can help. Contact us